Endocrine Pharmacology Practice Questions

Q: Which of the following drugs is taken during the first part of the meal for the purpose of delaying absorption of dietary carbohydrates?

Acarbose. **Explanation:** **Acarbose** is the correct answer because it belongs to the class of **Alpha-glucosidase inhibitors**. These drugs act locally in the small intestine to competitively inhibit the enzyme alpha-glucosidase, which is responsible for breaking down complex carbohydrates (oligosaccharides and disaccharides) into absorbable monosaccharides like glucose. By delaying carbohydrate digestion, they flatten the postprandial blood glucose curve. To be effective, the drug must be present in the gut simultaneously with the food; hence, it is taken at the **start of a meal (first bite).** **Why the other options are incorrect:** * **Glipizide (Sulfonylurea):** Acts by stimulating insulin secretion from pancreatic beta cells (insulin secretagogue). It is typically taken 30 minutes before a meal to allow for adequate absorption and onset of action. * **Nateglinide (Meglitinide):** Also an insulin secretagogue but with a rapid onset and short duration. It is taken just before a meal to control postprandial spikes, but it does not affect carbohydrate absorption. * **Pioglitazone (Thiazolidinedione):** Acts as a PPAR-gamma agonist to increase peripheral insulin sensitivity. Its effect is mediated via gene transcription and is not related to the timing of meal ingestion or carbohydrate absorption. **High-Yield NEET-PG Pearls:** * **Side Effects:** The most common side effects of Acarbose are GI-related: flatulence, bloating, and diarrhea (due to fermentation of undigested carbs by colonic bacteria). * **Hypoglycemia Management:** If a patient on Acarbose develops hypoglycemia (usually due to concurrent insulin or sulfonylureas), they must be treated with **pure glucose (dextrose)**, not sucrose (cane sugar), because Acarbose prevents the breakdown of sucrose. * **Contraindications:** Avoid in patients with Inflammatory Bowel Disease (IBD) or intestinal obstruction.

Q: Which of the following is NOT an adverse effect of growth hormone therapy?

Hypoglycemia. Growth hormone (GH) therapy is primarily used for GH deficiency, Turner syndrome, and Prader-Willi syndrome. Understanding its metabolic and structural effects is crucial for the NEET-PG exam.### Why Hypoglycemia is the Correct AnswerGrowth hormone is a **diabetogenic hormone**. It antagonizes the action of insulin, decreases peripheral glucose uptake, and increases hepatic gluconeogenesis. Therefore, the adverse effect associated with GH therapy is **Hyperglycemia** [1], not hypoglycemia. Chronic use can lead to glucose intolerance and overt diabetes mellitus.### Explanation of Incorrect Options* **Carpal Tunnel Syndrome:** GH stimulates the growth of connective tissue and promotes fluid retention (sodium/water). This can lead to edema and compression of the median nerve within the carpal tunnel [1].* **Intracranial Hypertension (Pseudotumor Cerebri):** This is a rare but classic side effect, especially in children. It presents with headache, visual changes, and papilledema, usually occurring early in treatment [1, 2].* **Slipped Capital Femoral Epiphysis (SCFE):** Rapid longitudinal bone growth induced by GH can put mechanical stress on the growth plate, leading to displacement of the femoral head [1].### High-Yield Clinical Pearls for NEET-PG* **Metabolic Effect:** GH increases lean body mass (anabolic) and decreases fat mass (lipolytic).* **IGF-1:** Most of the growth-promoting effects of GH are mediated by **Insulin-like Growth Factor-1 (IGF-1)**, produced mainly in the liver.* **Contraindication:** GH therapy is contraindicated in patients with active malignancy (due to its proliferative effects) and in those with closed epiphyses (if used for height).* **Pancreatitis:** Though rare, GH therapy has been associated with an increased risk of acute pancreatitis [1].

Q: What is the medical management of insulinoma?

Diazoxide. **Explanation:** **Insulinoma** is a rare neuroendocrine tumor of the pancreas that secretes excessive insulin, leading to severe fasting hypoglycemia. While surgical resection is the definitive treatment, medical management is required for patients who are non-surgical candidates or have metastatic disease. **Why Diazoxide is the Correct Answer:** Diazoxide is the drug of choice for the medical management of insulinoma. It acts as a **K+ channel opener** (specifically the ATP-sensitive potassium channels) in the pancreatic beta cells. By keeping these channels open, it hyperpolarizes the cell membrane, thereby inhibiting the release of insulin. Additionally, it stimulates glucose release from the liver and enhances catecholamine response, collectively raising blood glucose levels. **Analysis of Incorrect Options:** * **Octreotide:** While this somatostatin analog can inhibit insulin release, its effect is unpredictable. In some patients, it may also inhibit Growth Hormone and Glucagon, potentially worsening hypoglycemia. It is generally considered a second-line agent. * **Streptozotocin:** This is a nitrosourea alkylating agent that is specifically cytotoxic to pancreatic beta cells. It is used for **chemical ablation** in malignant insulinomas rather than routine medical management of symptoms. * **Somatomedin:** Also known as Insulin-like Growth Factor (IGF), it has insulin-like effects and would worsen hypoglycemia. It has no role in treating insulinoma. **High-Yield Clinical Pearls for NEET-PG:** * **Whipple’s Triad:** Symptoms of hypoglycemia, low plasma glucose (<50 mg/dL), and relief of symptoms after glucose administration (diagnostic for insulinoma). * **Diazoxide Side Effect:** A notable side effect is **sodium and water retention** (often requiring diuretics) and **hypertrichosis** (excessive hair growth). * **Alternative:** If Diazoxide fails, **Everolimus** (an mTOR inhibitor) is increasingly used for malignant insulinomas.

Q: A pregnant female is taking carbimazole. Which of the following is not seen in the neonate?

Cleft lip/palate. **Explanation:** The question addresses the teratogenic profile of antithyroid drugs. **Carbimazole** is a prodrug of **Methimazole**. Both are associated with a specific pattern of malformations known as **Methimazole Embryopathy** when used during the first trimester of pregnancy. **Why Cleft lip/palate is the correct answer:** Cleft lip and palate are not part of the classic Methimazole Embryopathy. While they are common congenital anomalies, they are not specifically linked to carbimazole exposure. In contrast, the drug is notorious for causing specific midline and craniofacial defects. **Analysis of incorrect options:** * **Choanal atresia (Option A):** This is a hallmark feature of Methimazole Embryopathy. It involves the narrowing or blockage of the nasal airway. * **Scalp defects (Option B):** Specifically **Aplasia Cutis Congenita** (focal absence of skin on the scalp) is a highly characteristic side effect of carbimazole/methimazole. * **Fetal goiter (Option D):** All antithyroid drugs (including PTU) cross the placenta and can inhibit the fetal thyroid gland, leading to increased TSH levels and subsequent fetal goiter and hypothyroidism. **High-Yield Clinical Pearls for NEET-PG:** * **Drug of Choice (DOC):** **Propylthiouracil (PTU)** is the DOC in the **1st trimester** because it is more protein-bound, crosses the placenta less readily, and is not associated with aplasia cutis. * **Switching:** Many guidelines recommend switching from PTU to Methimazole in the **2nd and 3rd trimesters** to avoid PTU-induced maternal hepatotoxicity. * **Other Methimazole effects:** Esophageal atresia and tracheoesophageal fistula are also seen.

Q: Which medication is used in the treatment of idiopathic central precocious puberty?

GnRH analogues. **Explanation:** **Central Precocious Puberty (CPP)** is caused by the premature activation of the hypothalamic-pituitary-gonadal (HPG) axis, leading to early secretion of GnRH and subsequent elevation of LH and FSH. **Why GnRH Analogues are correct:** The treatment of choice for CPP is **continuous administration of long-acting GnRH analogues** (e.g., Leuprolide, Goserelin, Nafarelin). While physiological GnRH is released in a pulsatile manner to stimulate the pituitary, continuous (non-pulsatile) administration leads to **downregulation and desensitization of GnRH receptors** on pituitary gonadotropes. This results in a paradoxical suppression of LH and FSH secretion, effectively "halting" pubertal progression and preventing premature epiphyseal closure, thereby preserving adult height. **Why other options are incorrect:** * **Exogenous Gonadotrophins (LH/FSH):** These would further stimulate the ovaries/testes, worsening the precocious puberty. They are used in treating infertility, not CPP. * **Ethinyl Estradiol:** This is a synthetic estrogen. Administering it would accelerate secondary sexual characteristics and bone age maturation, which is the opposite of the treatment goal. **High-Yield Clinical Pearls for NEET-PG:** * **Drug of Choice:** Leuprolide acetate (long-acting depot) is the most commonly used GnRH analogue. * **Monitoring:** The goal is to maintain prepubertal levels of LH and sex steroids. * **Bone Age:** Treatment is typically continued until the child reaches an appropriate age for puberty to prevent short stature. * **Diagnostic Test:** The gold standard for diagnosing CPP is the **GnRH stimulation test** (showing a pubertal LH response).

Q: Which of the following agents does NOT decrease bone resorption in osteoporosis?

Teriparatide. **Explanation:** The management of osteoporosis involves two main classes of drugs: **Antiresorptive agents** (which inhibit osteoclast activity) and **Anabolic agents** (which stimulate osteoblast activity to form new bone). **Why Teriparatide is the correct answer:** Teriparatide is a recombinant form of human **Parathyroid Hormone (PTH 1-34)**. Unlike continuous high levels of endogenous PTH which cause bone loss, **intermittent (once-daily)** administration of Teriparatide stimulates **osteoblasts** more than osteoclasts. This leads to a net increase in bone mineral density (BMD) and improved bone architecture. Therefore, it is an **anabolic agent**, not an antiresorptive one. **Analysis of Incorrect Options:** * **Alendronate & Etidronate (Bisphosphonates):** These are the prototypical **antiresorptive** agents. They concentrate at sites of active remodeling and inhibit the enzyme *farnesyl pyrophosphate synthase* in osteoclasts, leading to osteoclast apoptosis and decreased bone resorption. * **Strontium Ranelate:** This agent has a **dual mechanism of action**. It both increases bone formation (anabolic) and decreases bone resorption (antiresorptive). Since it does decrease resorption, it is not the correct choice for this "NOT" question. **High-Yield Clinical Pearls for NEET-PG:** * **Teriparatide Limit:** Due to a theoretical risk of **Osteosarcoma** (seen in rat studies), its use is typically limited to a maximum of 2 years. * **Denosumab:** A monoclonal antibody against **RANKL**; it is a potent antiresorptive agent. * **Bisphosphonates Side Effect:** The most common is esophageal irritation; the most "high-yield" for exams are **Osteonecrosis of the Jaw (ONJ)** and **Atypical Subtrochanteric Fractures** with long-term use. * **First-line:** Bisphosphonates remain the first-line treatment for most patients with osteoporosis.

Q: What is the pharmacological classification of Clomiphene?

Oestrogen partial agonist. **Explanation:** **Clomiphene Citrate** is a non-steroidal compound classified as a **Selective Estrogen Receptor Modulator (SERM)**. It acts as a **partial agonist** at estrogen receptors (ER). The mechanism of action relies on its ability to bind to ERs in the hypothalamus and anterior pituitary, competing with endogenous estrogen. Because it is a partial agonist with low intrinsic activity, it effectively acts as an **antagonist** in these tissues. By blocking the negative feedback of estrogen, it triggers an increase in the secretion of GnRH, FSH, and LH. This "surge" in gonadotrophins stimulates follicular development in the ovaries, making it the drug of choice for **ovulation induction** in infertility (e.g., PCOS). **Analysis of Incorrect Options:** * **A. Anti-gonadotrophin:** Clomiphene actually *increases* gonadotrophin levels (FSH/LH). Drugs like Danazol or GnRH analogues (in continuous doses) are anti-gonadotrophic. * **B. Progesterone antagonist:** These are drugs like Mifepristone, used for medical abortion or emergency contraception. * **D. Anti-androgenic:** These include drugs like Cyproterone or Spironolactone, used to treat hirsutism or prostate cancer. **High-Yield Clinical Pearls for NEET-PG:** * **Indication:** First-line for infertility due to anovulation (provided the pituitary-ovarian axis is intact). * **Side Effects:** Multiple pregnancies (mostly twins), ovarian hyperstimulation syndrome (OHSS), and vasomotor flushes. * **Contraindication:** It should not be used in patients with liver disease or ovarian cysts. * **Key Distinction:** While it is a partial agonist, its clinical effect in the CNS is primarily **antagonistic**, which is why it is often grouped with "anti-estrogens" in older textbooks.

Q: Strontium ranelate is approved for treatment of:

Osteoporosis. **Explanation:** **Strontium ranelate** is a unique pharmacological agent used in the management of **postmenopausal osteoporosis** and osteoporosis in men. It is classified as a **Dual Acting Bone Agent (DABA)** because it possesses a unique "dual mechanism of action": 1. **Anabolic effect:** It stimulates osteoblast proliferation and increases collagen synthesis, leading to increased bone formation. 2. **Antiresorptive effect:** It inhibits osteoclast differentiation and activity, thereby reducing bone resorption. This dual action results in a net increase in Bone Mineral Density (BMD) and a reduction in the risk of vertebral and hip fractures. **Analysis of Incorrect Options:** * **Asthma:** Managed with bronchodilators (Beta-2 agonists) and anti-inflammatory agents (Corticosteroids). Strontium has no effect on airway smooth muscle or inflammation. * **Cystic Fibrosis:** Primarily treated with mucolytics, CFTR modulators (like Ivacaftor), and antibiotics. * **Urinary Tract Infection (UTI):** Requires antimicrobial therapy (e.g., Nitrofurantoin, Fosfomycin, or Fluoroquinolones). **High-Yield Clinical Pearls for NEET-PG:** * **Administration:** It is taken as a sachet dissolved in water, ideally at bedtime, at least 2 hours after food (calcium in food/dairy interferes with its absorption). * **Side Effects:** The most common side effects are nausea and diarrhea. * **Contraindications/Safety:** Due to an increased risk of **cardiovascular events** (myocardial infarction) and **Venous Thromboembolism (VTE)**, its use is now restricted to patients with severe osteoporosis who cannot use other treatments and have no history of ischemic heart disease, peripheral arterial disease, or uncontrolled hypertension. * **DREMS Syndrome:** It is rarely associated with Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS).

Q: Desmopressin acts on ______ receptors to increase the release of VWF and factor VIII from endothelium?

V2. **Explanation:** Desmopressin (dDAVP) is a synthetic analogue of Vasopressin (ADH) with a modified structure that increases its selectivity and duration of action. **Why V2 is Correct:** Vasopressin receptors are G-protein coupled receptors. While **V2 receptors** are primarily known for their role in the renal collecting ducts (mediating water reabsorption via Aquaporin-2), they are also located on **vascular endothelial cells**. Stimulation of these extra-renal V2 receptors triggers the exocytosis of Weibel-Palade bodies, leading to the release of **von Willebrand Factor (vWF)** and **Factor VIII**. This makes Desmopressin a first-line treatment for mild Hemophilia A and von Willebrand Disease (Type 1). **Why other options are incorrect:** * **V1 (V1a):** These receptors are located on vascular smooth muscle. Their activation causes **vasoconstriction** and increases peripheral resistance. Desmopressin has minimal V1 activity compared to natural Vasopressin, which is why it does not cause significant hypertension. * **V3 (V1b):** These are found in the **anterior pituitary**, where they mediate the release of ACTH. * **V4:** There is no clinically recognized V4 receptor in human pharmacology related to vasopressin. **High-Yield Clinical Pearls for NEET-PG:** * **Route of Administration:** Desmopressin can be given intranasally, IV, or orally. * **Drug of Choice (DOC):** Central Diabetes Insipidus and Nocturnal Enuresis. * **Side Effect:** The most serious side effect is **dilutional hyponatremia**, which can lead to seizures. * **Tachyphylaxis:** Repeated doses can lead to a diminished response due to the depletion of endothelial stores of vWF.

Q: Chronic use of which of the following medications is most likely to cause osteoporosis?

Prednisone. **Explanation:** **Correct Option: D (Prednisone)** Glucocorticoids like Prednisone are the most common cause of **drug-induced osteoporosis**. They induce bone loss through a multi-factorial mechanism: 1. **Decreased Bone Formation:** They inhibit osteoblast proliferation and activity while increasing osteocyte apoptosis. 2. **Increased Bone Resorption:** They increase the expression of RANK-ligand (RANKL) and decrease Osteoprotegerin (OPG), leading to enhanced osteoclast activity. 3. **Calcium Imbalance:** They decrease intestinal calcium absorption and increase renal calcium excretion, leading to secondary hyperparathyroidism. **Analysis of Incorrect Options:** * **A. Lovastatin:** Statins are generally considered bone-neutral. Some studies even suggest they may have a mild protective effect on bone by increasing BMP-2 (Bone Morphogenetic Protein) expression. * **B. Propranolol:** Beta-blockers are not associated with osteoporosis. In fact, research into the sympathetic nervous system's role in bone remodeling suggests that beta-blockers might potentially increase bone mineral density. * **C. Warfarin:** While long-term Vitamin K antagonism can theoretically interfere with the gamma-carboxylation of osteocalcin (a bone protein), it is not a primary or classic cause of clinical osteoporosis compared to steroids. **High-Yield Clinical Pearls for NEET-PG:** * **Glucocorticoid-Induced Osteoporosis (GIOP):** Bone loss is most rapid in the first 3–6 months of therapy. * **Prophylaxis:** Patients on long-term steroids (>3 months) should be supplemented with Calcium and Vitamin D. **Bisphosphonates** (e.g., Alendronate) are the first-line treatment for prevention and management. * **Other Drugs causing Osteoporosis:** Heparin (long-term), Phenytoin, Carbamazepine, Aromatase inhibitors, and Proton Pump Inhibitors (PPIs).

Question 1

Which of the following drugs is taken during the first part of the meal for the purpose of delaying absorption of dietary carbohydrates?

Accepted Answer

Acarbose

Answer

Glipizide

Answer

Nateglinide

Answer

Pioglitazone

Question 2

Which of the following is NOT an adverse effect of growth hormone therapy?

Accepted Answer

Hypoglycemia

Answer

Carpal tunnel syndrome

Answer

Intracranial hypertension

Answer

Slipped femoral epiphysis

Question 3

What is the medical management of insulinoma?

Accepted Answer

Diazoxide

Answer

Octreotide

Answer

Streptozotocin

Answer

Somatomedin

Question 4

A pregnant female is taking carbimazole. Which of the following is not seen in the neonate?

Accepted Answer

Cleft lip/palate

Answer

Choanal atresia

Answer

Scalp defects

Answer

Fetal goiter

Question 5

Which medication is used in the treatment of idiopathic central precocious puberty?

Accepted Answer

GnRH analogues

Answer

Exogenous gonadotrophins

Answer

Ethinyl estradiol

Answer

Ethinyl estradiol

Question 6

Which of the following agents does NOT decrease bone resorption in osteoporosis?

Accepted Answer

Teriparatide

Answer

Alendronate

Answer

Etidronate

Answer

Strontium

Question 7

What is the pharmacological classification of Clomiphene?

Accepted Answer

Oestrogen partial agonist

Answer

Anti-gonadotrophin

Answer

Progesterone antagonist

Answer

Anti-androgenic

Question 8

Strontium ranelate is approved for treatment of:

Accepted Answer

Osteoporosis

Answer

Asthma

Answer

Cystic fibrosis

Answer

Urinary tract infection

Question 9

Desmopressin acts on ______ receptors to increase the release of VWF and factor VIII from endothelium?

Accepted Answer

V2

Answer

V1

Answer

V3

Answer

V4

Question 10

Chronic use of which of the following medications is most likely to cause osteoporosis?

Accepted Answer

Prednisone

Answer

Lovastatin

Answer

Propranolol

Answer

Warfarin

Endocrine Pharmacology — MCQs

Endocrine Pharmacology — MCQs

On this page

Practice by Chapter

Want unlimited practice?